메뉴 건너뛰기




Volumn 12, Issue 1, 2014, Pages 16-26

Management of hepatitis B: Our practice and how it relates to the guidelines

Author keywords

Antiviral Therapy; Chronic Hepatitis B; Hepatitis B Guidelines; Management

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; DNA; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B CORE ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERLEUKIN 28B; LAMIVUDINE; PEGINTERFERON; RITUXIMAB; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT;

EID: 84890244680     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.04.036     Document Type: Article
Times cited : (82)

References (40)
  • 1
    • 70349240414 scopus 로고    scopus 로고
    • Chronic hepatitis B: update 2009
    • Lok A.S., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009, 50:661-662.
    • (2009) Hepatology , vol.50 , pp. 661-662
    • Lok, A.S.1    McMahon, B.J.2
  • 2
    • 84862664371 scopus 로고    scopus 로고
    • EASL clinical practice guidelines: management of chronic hepatitis B virus infection
    • EASL clinical practice guidelines: management of chronic hepatitis B virus infection. JHepatol 2012, 57:167-185.
    • (2012) JHepatol , vol.57 , pp. 167-185
  • 3
    • 84865376141 scopus 로고    scopus 로고
    • Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
    • Liaw Y.F., Kao J.H., Piratvisuth T., et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012, 6:531-561.
    • (2012) Hepatol Int , vol.6 , pp. 531-561
    • Liaw, Y.F.1    Kao, J.H.2    Piratvisuth, T.3
  • 4
    • 34247268523 scopus 로고    scopus 로고
    • Navigating the maze of hepatitis B treatments
    • Lok A.S. Navigating the maze of hepatitis B treatments. Gastroenterology 2007, 132:1586-1594.
    • (2007) Gastroenterology , vol.132 , pp. 1586-1594
    • Lok, A.S.1
  • 5
    • 29944436855 scopus 로고    scopus 로고
    • Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level
    • Chen C.J., Yang H.I., Su J., et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006, 295:65-73.
    • (2006) JAMA , vol.295 , pp. 65-73
    • Chen, C.J.1    Yang, H.I.2    Su, J.3
  • 6
    • 33644858331 scopus 로고    scopus 로고
    • Predicting cirrhosis risk based on the level of circulating hepatitis B viral load
    • Iloeje U.H., Yang H.I., Su J., et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006, 130:678-686.
    • (2006) Gastroenterology , vol.130 , pp. 678-686
    • Iloeje, U.H.1    Yang, H.I.2    Su, J.3
  • 7
    • 70449715760 scopus 로고    scopus 로고
    • Current management of hepatitis B virus infection before and after liver transplantation
    • Papatheodoridis G.V., Cholongitas E., Archimandritis A.J., et al. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009, 29:1294-1305.
    • (2009) Liver Int , vol.29 , pp. 1294-1305
    • Papatheodoridis, G.V.1    Cholongitas, E.2    Archimandritis, A.J.3
  • 8
    • 19544391413 scopus 로고    scopus 로고
    • Lamivudine for patients with chronic hepatitis B and advanced liver disease
    • Liaw Y.F., Sung J.J., Chow W.C., et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. NEngl J Med 2004, 351:1521-1531.
    • (2004) NEngl J Med , vol.351 , pp. 1521-1531
    • Liaw, Y.F.1    Sung, J.J.2    Chow, W.C.3
  • 9
    • 84873726484 scopus 로고    scopus 로고
    • Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
    • Marcellin P., Gane E., Buti M., et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013, 381:468-475.
    • (2013) Lancet , vol.381 , pp. 468-475
    • Marcellin, P.1    Gane, E.2    Buti, M.3
  • 10
    • 59149096271 scopus 로고    scopus 로고
    • Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study
    • Xu W.M., Cui Y.T., Wang L., et al. Lamivudine in late pregnancy to prevent perinatal transmission of hepatitis B virus infection: a multicentre, randomized, double-blind, placebo-controlled study. JViral Hepat 2009, 16:94-103.
    • (2009) JViral Hepat , vol.16 , pp. 94-103
    • Xu, W.M.1    Cui, Y.T.2    Wang, L.3
  • 11
    • 81355161368 scopus 로고    scopus 로고
    • Aprospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection
    • Han G.R., Cao M.K., Zhao W., et al. Aprospective and open-label study for the efficacy and safety of telbivudine in pregnancy for the prevention of perinatal transmission of hepatitis B virus infection. JHepatol 2011, 55:1215-1221.
    • (2011) JHepatol , vol.55 , pp. 1215-1221
    • Han, G.R.1    Cao, M.K.2    Zhao, W.3
  • 12
    • 42249113025 scopus 로고    scopus 로고
    • Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy
    • Loomba R., Rowley A., Wesley R., et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008, 148:519-528.
    • (2008) Ann Intern Med , vol.148 , pp. 519-528
    • Loomba, R.1    Rowley, A.2    Wesley, R.3
  • 13
    • 79952231921 scopus 로고    scopus 로고
    • Management of hepatocellular carcinoma: an update
    • Bruix J., Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
    • (2011) Hepatology , vol.53 , pp. 1020-1022
    • Bruix, J.1    Sherman, M.2
  • 14
    • 84858658381 scopus 로고    scopus 로고
    • EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma
    • EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. JHepatol 2012, 56:908-943.
    • (2012) JHepatol , vol.56 , pp. 908-943
  • 15
    • 84984586846 scopus 로고    scopus 로고
    • Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma
    • Omata M., Lesmana L.A., Tateishi R., et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010, 4:439-474.
    • (2010) Hepatol Int , vol.4 , pp. 439-474
    • Omata, M.1    Lesmana, L.A.2    Tateishi, R.3
  • 16
    • 84860304268 scopus 로고    scopus 로고
    • Effectiveness of hepatitis B treatment in clinical practice
    • e1361
    • Scaglione S.J., Lok A.S. Effectiveness of hepatitis B treatment in clinical practice. Gastroenterology 2012, 142:1360-1368. e1361.
    • (2012) Gastroenterology , vol.142 , pp. 1360-1368
    • Scaglione, S.J.1    Lok, A.S.2
  • 17
    • 21244447705 scopus 로고    scopus 로고
    • Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B
    • Lau G.K., Piratvisuth T., Luo K.X., et al. Peginterferon alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. NEngl J Med 2005, 352:2682-2695.
    • (2005) NEngl J Med , vol.352 , pp. 2682-2695
    • Lau, G.K.1    Piratvisuth, T.2    Luo, K.X.3
  • 18
    • 4544239807 scopus 로고    scopus 로고
    • Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B
    • Marcellin P., Lau G.K., Bonino F., et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. NEngl J Med 2004, 351:1206-1217.
    • (2004) NEngl J Med , vol.351 , pp. 1206-1217
    • Marcellin, P.1    Lau, G.K.2    Bonino, F.3
  • 19
    • 48549107919 scopus 로고    scopus 로고
    • Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b
    • Buster E.H., Flink H.J., Cakaloglu Y., et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008, 135:459-467.
    • (2008) Gastroenterology , vol.135 , pp. 459-467
    • Buster, E.H.1    Flink, H.J.2    Cakaloglu, Y.3
  • 20
    • 66449121130 scopus 로고    scopus 로고
    • Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a
    • e2161-2164
    • Marcellin P., Bonino F., Lau G.K., et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009, 136:2169-2179. e2161-2164.
    • (2009) Gastroenterology , vol.136 , pp. 2169-2179
    • Marcellin, P.1    Bonino, F.2    Lau, G.K.3
  • 21
    • 70649104668 scopus 로고    scopus 로고
    • Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa
    • Buster E.H., Hansen B.E., Lau G.K., et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009, 137:2002-2009.
    • (2009) Gastroenterology , vol.137 , pp. 2002-2009
    • Buster, E.H.1    Hansen, B.E.2    Lau, G.K.3
  • 22
    • 65449117946 scopus 로고    scopus 로고
    • Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B
    • Brunetto M.R., Moriconi F., Bonino F., et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009, 49:1141-1150.
    • (2009) Hepatology , vol.49 , pp. 1141-1150
    • Brunetto, M.R.1    Moriconi, F.2    Bonino, F.3
  • 23
    • 65449123444 scopus 로고    scopus 로고
    • Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients
    • Moucari R., Mackiewicz V., Lada O., et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009, 49:1151-1157.
    • (2009) Hepatology , vol.49 , pp. 1151-1157
    • Moucari, R.1    Mackiewicz, V.2    Lada, O.3
  • 24
    • 84874471701 scopus 로고    scopus 로고
    • IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B
    • Lampertico P., Vigano M., Cheroni C., et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013, 57:890-896.
    • (2013) Hepatology , vol.57 , pp. 890-896
    • Lampertico, P.1    Vigano, M.2    Cheroni, C.3
  • 25
    • 75449107726 scopus 로고    scopus 로고
    • Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B
    • Chang T.T., Lai C.L., Kew Yoon S., et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010, 51:422-430.
    • (2010) Hepatology , vol.51 , pp. 422-430
    • Chang, T.T.1    Lai, C.L.2    Kew Yoon, S.3
  • 26
    • 66149115173 scopus 로고    scopus 로고
    • Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy
    • Tenney D.J., Rose R.E., Baldick C.J., et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009, 49:1503-1514.
    • (2009) Hepatology , vol.49 , pp. 1503-1514
    • Tenney, D.J.1    Rose, R.E.2    Baldick, C.J.3
  • 27
    • 33744531146 scopus 로고    scopus 로고
    • Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B
    • Sherman M., Yurdaydin C., Sollano J., et al. Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology 2006, 130:2039-2049.
    • (2006) Gastroenterology , vol.130 , pp. 2039-2049
    • Sherman, M.1    Yurdaydin, C.2    Sollano, J.3
  • 28
    • 33644818518 scopus 로고    scopus 로고
    • Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B
    • Chang T.T., Gish R.G., de Man R., et al. Acomparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. NEngl J Med 2006, 354:1001-1010.
    • (2006) NEngl J Med , vol.354 , pp. 1001-1010
    • Chang, T.T.1    Gish, R.G.2    de Man, R.3
  • 29
    • 18444367980 scopus 로고    scopus 로고
    • Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B
    • Perrillo R.P., Lai C.L., Liaw Y.F., et al. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186-194.
    • (2002) Hepatology , vol.36 , pp. 186-194
    • Perrillo, R.P.1    Lai, C.L.2    Liaw, Y.F.3
  • 30
    • 84865490229 scopus 로고    scopus 로고
    • Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B
    • e611
    • Lok A.S., Trinh H., Carosi G., et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B. Gastroenterology 2012, 143:619-628. e611.
    • (2012) Gastroenterology , vol.143 , pp. 619-628
    • Lok, A.S.1    Trinh, H.2    Carosi, G.3
  • 31
    • 58649096155 scopus 로고    scopus 로고
    • 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B
    • Liaw Y.F., Gane E., Leung N., et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009, 136:486-495.
    • (2009) Gastroenterology , vol.136 , pp. 486-495
    • Liaw, Y.F.1    Gane, E.2    Leung, N.3
  • 32
    • 73149085984 scopus 로고    scopus 로고
    • Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function
    • Lange C.M., Bojunga J., Hofmann W.P., et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009, 50:2001-2006.
    • (2009) Hepatology , vol.50 , pp. 2001-2006
    • Lange, C.M.1    Bojunga, J.2    Hofmann, W.P.3
  • 33
    • 51349107091 scopus 로고    scopus 로고
    • Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B
    • Marcellin P., Chang T.T., Lim S.G., et al. Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2008, 48:750-758.
    • (2008) Hepatology , vol.48 , pp. 750-758
    • Marcellin, P.1    Chang, T.T.2    Lim, S.G.3
  • 34
    • 78751491184 scopus 로고    scopus 로고
    • Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease
    • Liaw Y.F., Sheen I.S., Lee C.M., et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011, 53:62-72.
    • (2011) Hepatology , vol.53 , pp. 62-72
    • Liaw, Y.F.1    Sheen, I.S.2    Lee, C.M.3
  • 35
    • 79959551969 scopus 로고    scopus 로고
    • Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study
    • Liaw Y.F., Raptopoulou-Gigi M., Cheinquer H., et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011, 54:91-100.
    • (2011) Hepatology , vol.54 , pp. 91-100
    • Liaw, Y.F.1    Raptopoulou-Gigi, M.2    Cheinquer, H.3
  • 36
    • 75449093009 scopus 로고    scopus 로고
    • Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B
    • Lee H.W., Lee H.J., Hwang J.S., et al. Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology 2010, 51:415-421.
    • (2010) Hepatology , vol.51 , pp. 415-421
    • Lee, H.W.1    Lee, H.J.2    Hwang, J.S.3
  • 37
    • 84865487986 scopus 로고    scopus 로고
    • Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir
    • e621
    • Hadziyannis S.J., Sevastianos V., Rapti I., et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012, 143:629-636. e621.
    • (2012) Gastroenterology , vol.143 , pp. 629-636
    • Hadziyannis, S.J.1    Sevastianos, V.2    Rapti, I.3
  • 38
    • 84860320431 scopus 로고    scopus 로고
    • Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients
    • Epub ahead of print
    • Piratvisuth T., Marcellin P., Popescu M., et al. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int 2011, Epub ahead of print.
    • (2011) Hepatol Int
    • Piratvisuth, T.1    Marcellin, P.2    Popescu, M.3
  • 39
    • 77957958049 scopus 로고    scopus 로고
    • Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline
    • Sonneveld M.J., Rijckborst V., Boucher C.A., et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010, 52:1251-1257.
    • (2010) Hepatology , vol.52 , pp. 1251-1257
    • Sonneveld, M.J.1    Rijckborst, V.2    Boucher, C.A.3
  • 40
    • 79952227475 scopus 로고    scopus 로고
    • No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus
    • Snow-Lampart A., Chappell B., Curtis M., et al. No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virus. Hepatology 2011, 53:763-773.
    • (2011) Hepatology , vol.53 , pp. 763-773
    • Snow-Lampart, A.1    Chappell, B.2    Curtis, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.